2025 Poster Presentations

P01: Pathologic Complete Response in MSI-H Gastric Cancer Complicated by Severe Immune-Related Bone Marrow Toxicity, Presented by Oladimeji L., Atrium Health

P02: A Proven and Reliable Alpaca VHH Antibody Discovery Platform, Presented by Huanyi Y., Biointron Biological

P03: Simplified and Humanized: Empowering Humanized Antibody Discovery with AbDrop™ Solution, Presented by Haoming Z., Biointron Biological

P04: Triple-Negative Breast Cancer Patient-Derived Xenografts as Translational Models for Drug and Immunotherapy Development, Presented by Joseph H., EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH

P05: Ab-ility™ - An In-Silico Analysis and Developability Engineering Platform, Presented by Richard B., Fusion Antibodies plc

P06: OptiMAL®: Mammalian Display for Antibody Discovery, Presented by Olivier T., Fusion Antibodies plc

P07: Stimulation and Expansion of Antigen-Specific T Cells, Presented by Chris C., Immudex USA

P08: Specificity Testing of Antibodies, Multispecifics, and CAR-T Therapeutics for IND Using the Membrane Proteome Array, Presented by Peyton C., Integral Molecular

P09: Up to One-Third of Antibody Drugs Are Nonspecific: A Systematic Evaluation of Drugs Throughout Clinical and Preclinical Development, Presented by Alexander H., Integral Molecular

P10: A mCD3xEpCAM-mIL-15 Fusion Molecule Improves T Cell Engager Mediated Anti-Tumor Immunity, Presented by Ritama P., Johnson & Johnson

P11: A Novel Assay that Reveals Single-Cell Kinetic Changes in T-Cell Protein Expression During Activation, Presented by Sheldon K., LASE Innovation, Inc.

P12: Virus-Mediated Ex Vivo Destruction of Primary Triple Negative Breast Cancer Cells: Role of Non-Pathogenic Oncolytic Enteroviruses, Presented by Daria B., P. Hertsen Moscow Oncology Research Institute (MORI)

P13: Harnessing the Immune System: An N-of-1 Case Study in Integrative Cell Therapy & Naturopathic Oncology, Presented by David J., Naturopathic Specialists LLC

P14: A Human In Vitro Secondary Lymphoid Organ Model to Advance Immune-Modulatory Drug Development, Presented by Lotta H., Nexus Bioquest

P15: SIM0680, a Potent Antibody-Drug Conjugate(ADC) for the Treatment of Solid Tumors Expressing ENPP3, Presented by Jahnavi T., Simcere Innovation, Inc.

P16: Analysis of Multi Omics on Cells of Patients of CAR T Cell Immunotherapy, Specifically Comparing Cells Between Patients Who Have Gone Through Complete Remission vs. Patients Who Have Relapsed, Presented by Adam Y., The Hill School

P17: Rapid Design and Validation of Highly Specific Binders Against MHC-Peptide Targets, Presented by Manjima D., VCREATE